-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
With EPS Growth And More, LifeTech Scientific (HKG:1302) Makes An Interesting Case
With EPS Growth And More, LifeTech Scientific (HKG:1302) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like LifeTech Scientific (HKG:1302). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.
See our latest analysis for LifeTech Scientific
LifeTech Scientific's Earnings Per Share Are Growing
If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. It certainly is nice to see that LifeTech Scientific has managed to grow EPS by 31% per year over three years. If growth like this continues on into the future, then shareholders will have plenty to smile about.
It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. The music to the ears of LifeTech Scientific shareholders is that EBIT margins have grown from 10% to 40% in the last 12 months and revenues are on an upwards trend as well. Both of which are great metrics to check off for potential growth.
You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart.
SEHK:1302 Earnings and Revenue History August 1st 2022While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check LifeTech Scientific's balance sheet strength, before getting too excited.
Are LifeTech Scientific Insiders Aligned With All Shareholders?
It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own LifeTech Scientific shares worth a considerable sum. Indeed, they have a considerable amount of wealth invested in it, currently valued at CN¥2.0b. That equates to 17% of the company, making insiders powerful and aligned with other shareholders. Very encouraging.
Is LifeTech Scientific Worth Keeping An Eye On?
If you believe that share price follows earnings per share you should definitely be delving further into LifeTech Scientific's strong EPS growth. Further, the high level of insider ownership is impressive and suggests that the management appreciates the EPS growth and has faith in LifeTech Scientific's continuing strength. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. Of course, identifying quality businesses is only half the battle; investors need to know whether the stock is undervalued. So you might want to consider this free discounted cashflow valuation of LifeTech Scientific.
The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對於許多投資者,尤其是那些缺乏經驗的投資者來説,購買有好故事的公司的股票是很常見的,即使這些公司在虧損。有時,這些故事可能會矇蔽投資者的頭腦,導致他們以自己的情緒投資,而不是投資於良好的公司基本面。虧損的公司總是在爭分奪秒地實現財務可持續性,因此這些公司的投資者可能承擔了比他們應該承擔的更多的風險。
儘管處於科技股藍天投資的時代,許多投資者仍採取更傳統的策略;購買盈利的公司的股票,如生命科技科技(HKG:1302)。雖然這並不一定意味着它是否被低估了,但該業務的盈利能力足以證明它有一定的升值價值--特別是如果它在增長的話。
查看我們對LifeTech Science的最新分析
LifeTech Science的每股收益正在增長
如果一家公司能夠在足夠長的時間內保持每股收益(EPS)的增長,其股價最終應該會隨之而來。因此,有經驗的投資者在進行投資研究時密切關注公司每股收益是合理的。看到LifeTech Science在三年內以每年31%的速度增長每股收益,這當然是一件令人高興的事情。如果這樣的增長持續到未來,那麼股東們將有很多值得微笑的地方。
看一看息税前利潤(EBIT)利潤率和收入增長,對了解公司增長的質量通常是有幫助的。LifeTech Science股東聽到的消息是,在過去12個月裏,息税前利潤從10%增長到40%,收入也呈上升趨勢。這兩個都是衡量潛在增長的很好的指標。
你可以在下面的圖表中看到該公司的收入和收益增長趨勢。要查看實際數字,請點擊圖表。
聯交所:1302盈利及收入歷史2022年8月1日雖然看到利潤增長總是好事,但你應該始終記住,疲軟的資產負債表可能會回來產生影響。所以,在過於興奮之前,先看看LifeTech Science的資產負債表實力。
LifeTech Science內部人士是否與所有股東一致?
可以説,看到公司領導人把自己的錢拿來冒險是件令人高興的事情,因為這增加了企業經營者和真正的所有者之間的激勵一致性。股東將對內部人士持有價值相當大的LifeTech Science股票感到高興。事實上,他們有相當數量的財富投資於此,目前價值20億元人民幣。這相當於公司17%的股份,這讓內部人士變得強大,並與其他股東結盟。非常鼓舞人心。
生命科技值得關注嗎?
如果你相信股價跟隨每股收益,你肯定應該進一步研究LifeTech Science強勁的每股收益增長。此外,高水平的內部人持股令人印象深刻,表明管理層欣賞每股收益的增長,並對LifeTech Science的持續實力充滿信心。快速的增長和自信的內部人士應該足以證明有必要進行進一步的研究,因此它似乎是一隻值得追隨的好股票。當然,識別優質企業只是成功的一半;投資者需要知道股票是否被低估了。所以你可能會考慮這個免費LifeTech Science貼現現金流估值。
投資的美妙之處在於,你幾乎可以投資任何你想投資的公司。但如果你更願意關注那些表現出內幕收購的股票,這裏有一份過去三個月內有內幕收購的公司名單。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧